上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
MRT67307 纯度: 98.76%
MRT67307 是 IKKε 和 TBK-1 的双抑制剂,IC50 分别为 160 和 19 nM。MRT67307 也可抑制 ULK1 和 ULK2,IC50 分别为 45 和 38 nM。MRT67307 还抑制细胞自噬 (autophagy)。
MRT67307 Chemical Structure
CAS No. : 1190378-57-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥803 | In-stock | |
5 mg | ¥730 | In-stock | |
10 mg | ¥1300 | In-stock | |
50 mg | ¥4990 | In-stock | |
100 mg | ¥6500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
MRT67307 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Immunology/Inflammation Compound Library
- Kinase Inhibitor Library
- NF-κB Signaling Compound Library
- Stem Cell Signaling Compound Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Anti-Aging Compound Library
- Differentiation Inducing Compound Library
- Anti-Liver Cancer Compound Library
生物活性 |
MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively[1]. MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells[2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][2] |
|
||||||||||||||||
体外研究 (In Vitro) |
MRT67307 inhibits IKKϵ and TBK1 with IC50 values of 160 and 19 nM when assayed at 0.1 mM ATP in vitro, but did not inhibit IKKα or IKKβ even at 10 μM[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[3]
|
||||||||||||||||
分子量 |
464.60 |
||||||||||||||||
Formula |
C26H36N6O2 |
||||||||||||||||
CAS 号 |
1190378-57-4 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 100 mg/mL (215.24 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务